CHF Solutions Announces Distribution Agreement in India

EDEN PRAIRIE, Minn., Jan. 31, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced the initiation of a distribution agreement in the Indian market with Wayinia Lifesciences.  This agreement expands the company’s sales outreach in Asia, while opening new access to one of the larger population centers in the region.

Currently, there are around three million reports of heart failure in India, with an additional one million new incidents being reported annually.

“We continue to expand our presence worldwide and are pleased to extend the reach of our therapy with our Aquadex FlexFlow® system into the Indian healthcare centers for patients who are chronically challenged by fluid overload when diuretics have failed,” said John Erb, chairman and CEO of CHF Solutions.  “Heart failure is a global issue and there is a worldwide need to provide clinically proven tools to appropriately manage fluid overload.  We continue to grow our global presence and look forward to providing further updates as they become available.”

About Wayinia Lifesciences

Wayinia Lifesciences was established in 2015 with roots from India and Norway. The company is solely dedicated to improving people’s lives by bringing innovative healthcare technology and safety products from across the world to India.  Wayinia is dedicated to providing an international consulting platform to global healthcare and safety companies to offer their products in the Indian healthcare market.  Wayinia is working towards creating solutions and pathways to bring innovative medtech and safety companies to India.

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy.  The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.  All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.  The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology.  CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland.  The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the company’s plans to grow its global presence.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.  Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC.  Forward-looking statements speak only as of the date when made.   CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton

Chief Financial Officer

CHF Solutions, Inc.

952-345-4205

-or-



Bret Shapiro

Managing Partner

CORE IR

516-222-2560

MEDIA

Jules Abraham

JQA Partners, Inc.

917-885-7378